FNMA heads into the back half of August with a quiet week — up just over 1% to $6.29 — masking a more interesting story about where the Street has moved and what the borrow market is signalling about sentiment.
The borrow picture is unambiguously relaxed, and that tells you a lot about how short sellers view this one. Availability is running at roughly 586% — meaning there are nearly six shares available to borrow for every one already shorted — far above the 52-week tightest level of 362%. Cost to borrow has ticked up to 0.68%, its highest reading in a month, but in absolute terms that remains near-trivially cheap. Short interest itself is light, at 1.3% of the free float, and has drifted lower over the past month by nearly 4%. There is no short squeeze pressure here, and the data suggests short sellers are not building a meaningful position against the stock.
The most interesting action this week came from the analyst community, and the direction was downward. Following last month's Q2 earnings print — which saw the stock fall nearly 2% on the day and then shed another 8% over the following week — two firms moved promptly. B. Riley cut its price target from $8 to $7 while holding a Neutral rating. Wedbush initiated fresh coverage also at Neutral with an $8 target. The consensus mean target sits near $9.85, which implies meaningful upside from $6.29, but the active coverage is clustered around Neutral — a signal that the Street sees the optionality in a conservatorship exit without wanting to own it aggressively. KBW carries an Underperform rating. The negative price-to-book ratio (a structural artefact of FNMA's conservatorship balance sheet) and a PE multiple above 400 make conventional valuation comparisons largely uninformative.
The two dominant institutional holders tell the positioning story in miniature. Pershing Square, the highest-profile name on the register with roughly 2% of shares outstanding, has not changed its position. Capital Research also held flat through June. Neither is adding nor trimming — a kind of institutionalised patience that mirrors the broader conservatorship waiting game. Insider data is stale by more than a year, so it offers nothing useful here.
Where FNMA does stand out is on earnings revisions momentum. The EPS momentum scores rank in the 99th to 100th percentile over both 30 and 90-day windows — driven by a forward EPS increase of more than 100% year-on-year. That growth signal is real, but it coexists with a short score of 39, placing the stock in the lower third of the ORTEX universe for short-squeeze risk, consistent with the loose borrow market. Close GSE peer FMCC gained 2.7% on the week versus FNMA's 1.1%, though with a 97% return correlation the two tend to trade as a pair over any meaningful horizon.
The next scheduled catalyst is the Q3 earnings release on October 27. Given the pattern from the July print — where the five-day reaction erased more than the one-day gain and then some — the pace of any conservatorship policy news between now and then is likely to matter more to price direction than the earnings numbers themselves.
See the live data behind this article on ORTEX.
Open FNMA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
